About: Tositumomab and Iodine I 131 Tositumomab     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : owl:Class, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
rdfs:label
  • Tositumomab and Iodine I 131 Tositumomab
rdfs:subClassOf
Semantic_Type
  • Therapeutic or Preventive Procedure
Preferred_Name
  • Tositumomab and Iodine I 131 Tositumomab
NCI_META_CUI
  • CL378645
ALT_DEFINITION
  • A combination of monoclonal antibodies used to treat certain types of non-Hodgkin lymphoma. The monoclonal antibody tositumomab is given with iodine I 131 tositumomab (a form of tositumomab that has been chemically changed by adding radioactive iodine). Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells.NCI-GLOSS
PDQ_Open_Trial_Search_ID
  • 588881
PDQ_Closed_Trial_Search_ID
  • 588881
Legacy_Concept_Name
  • Tositumomab_I-131_Tositumomab
FULL_SYN
  • tositumomabPTNCI-GLOSSCDR0000367410
  • Bexxar TherapySYNCI
  • Bexxar Therapeutic RegimenSYNCI
  • tositumomab and iodine I 131 tositumomabPTNCI-GLOSSCDR0000588694
  • Bexxar regimenPTNCI-GLOSSCDR0000367411
  • Tositumomab and Iodine I 131 TositumomabPTNCI
DEFINITION
  • A murine IgG2a lambda monoclonal antibody, both unradiolabeled and radiolabeled with iodine I 131, directed against the human B cell-specific surface antigen CD20. Tositumomab binds to CD20, resulting in complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and apoptosis in B cells expressing CD20; in addition to the antibody-mediated cytotoxicity, iodine I 131 tositumomab delivers cytotoxic ionizing radiation specifically to CD20-expressing B cells. In a two-step therapeutic regimen, a predose of unradiolabeled tositumomab is administered first followed by the administration of a dosimetric dose of iodine I 131 tositumomab; 7-14 days later, a therapeutic dose of iodine I 131 tositumomab is administered. The predose of unradiolabeled tositumomab binds to nontumor B cells, increasing the terminal half-life of radiolabeled antibody while protecting nontumor B cells from radiolabeled antibody-mediated radiocytotoxicity.NCI
code
  • C72672
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 46 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software